B. pseudocatenulatum for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

B. pseudocatenulatum for Health & Longevity

Created on 08/27/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A gut bacterium that ferments plant fiber, more common in people reaching old age in good health. Evidence for taking it is thin: one small trial in children nudged inflammation and cholesterol markers; the rest is animal work or a pattern seen in surveys. Safety looks unremarkable in healthy adults. A sign of healthy aging is not a proven supplement. (Full Review)

Protocol

Established dose
10⁹–10¹⁰ CFU daily
No consensus dose exists; the only randomized trial used strain CECT 7765 for 13 weeks.
Best time of day
With or after a meal
Food buffers acid and improves survival to the colon; no circadian advantage tested.
Competing approach — prebiotic first
Xylooligosaccharides 1–2 g daily
Raises native bifidobacteria with no live organism; the practical route today, as no studied strain is broadly marketed.
Time to effect
Inflammatory and lipid markers
13 weeks
The interval at which the only human trial measured change; shorter reads nothing.
Stool bifidobacterial counts
14–28 days
Counts shift within this window on adequate substrate.
Persistence rather than half-life
1–2 weeks after stopping
Cleared over this period; supplemented bifidobacteria rarely establish permanently.

Benefits

Contraindications
  • Immunosuppressants (tacrolimus, high-dose corticosteroids) or cytotoxic chemotherapy during treatment
  • Neutropenia (neutrophil count below 500 cells/µL)
  • Solid organ or stem cell transplant on maintenance immunosuppression
  • Central venous catheter, or gastrointestinal surgery within 30 days
  • Short bowel syndrome, severe mucositis, gastrointestinal bleeding or perforation
  • Decompensated cirrhosis (Child-Pugh C), critical illness, severe acute pancreatitis
  • Impaired swallowing with high aspiration risk
  • Pregnancy and breastfeeding
    •
Key Interactions
  • Antibiotics (azithromycin, metronidazole)
  • Post-antibiotic timing
  • Bile acid sequestrants (cholestyramine), ursodeoxycholic acid
  • Acid suppressants (omeprazole, famotidine)
  • Antidiarrheals and bismuth subsalicylate
  • Prebiotic fibers (xylooligosaccharides, inulin)
  • Other Bifidobacterium and Lactobacillus probiotics
  • Anti-inflammatory supplements (omega-3, curcumin)
  • Antibacterial botanicals (berberine, oregano oil)
  • Fecal microbiota transplant, checkpoint inhibitors
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Bloodstream infection with impaired barriers; tumor tissue enrichment; infant eczema; delayed microbiome recovery after antibiotics
  • Speculative: Transferable antibiotic resistance genes; gastrointestinal symptoms at initiation; bile acid pool shifts

Monitoring

Marker Target Why
High-sensitivity C-reactive protein Below 1.0 mg/L (0.5 mg/L optimal) The single endpoint a human trial moved
HDL cholesterol 60–80 mg/dL (1.55–2.07 mmol/L) Rose in the human trial
Triglycerides Below 80 mg/dL (below 0.90 mmol/L) Bile acid and fermentation effects
Fasting insulin 2–5 µIU/mL The trial selected on insulin resistance
HbA1c 4.8–5.4% Confirms a metabolic shift is real
Fecal calprotectin Below 50 µg/g Translocation risk is highest here
Stool B. pseudocatenulatum relative abundance No established target; track change from own baseline Confirms the protocol shifted the organism
Complete blood count and comprehensive metabolic panel No established target; within laboratory reference range Safety readout, mirroring the registered trial

Cadence: Baseline, twelve weeks, then six-monthly; repeat stool sequencing only after a change of prebiotic, strain, or antibiotics.

Qualitative Assessment

  • Bowel habit — stool form and frequency, the fastest-moving signal of change
  • Bloating and flatulence, which peak in the first two weeks and settle if the dose suits
  • Abdominal discomfort, the symptom that improved in the uncontrolled synbiotic pilot
  • Energy through the afternoon, a crude proxy for slow-moving metabolic change
  • Cognitive clarity, given the observational link with cognition in older adults
  • Sleep quality, on the tryptophan mechanism proposed in animals but not tested in people
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.